PLUR
vs
C
CANF
PLUR
Over the past 12 months, PLUR has significantly outperformed CANF, delivering a return of -21% compared to the CANF's 89% drop.
Paid Plans
Want to analyze multiple companies at once? Paid plans let you compare up to 5 stocks side by side.
Sign Up
Smart Verdict
AI-Powered
Let AI Decide.
PLUR
Valuation Comparison
| Company | Last Price | Intrinsic Value | DCF Value | Relative Value | Wall St Target | ||
|---|---|---|---|---|---|---|---|
|
Pluri Inc
NASDAQ:PLUR
|
3.55
USD
|
|||||
|
C
|
Can Fite Biopharma Ltd
TASE:CANF
|
688
ILS
|
|||||
Compare the stock's valuation with its competitors.
Growth Comparison
Growth Over Time
PLUR, CANF
Compare company's financials with its competitors.
| Company | LTM | Historical Growth | Growth Streak | % Positive Years | Max Drawdown | Volatility | Forecasted Growth | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3 Years | 5 Years | 10 Years | 1 Year | 3 Years | ||||||||
|
Pluri Inc
Revenue
|
|||||||||||
|
C
|
Can Fite Biopharma Ltd
Revenue
|
|||||||||||
All metrics are calculated based on data from the last 10 years.
Compare company's financials with its competitors.
Profitability Comparison
Free Cash Flow
PLUR, CANF
Compare company's free cash flow with its competitors.
| Company | LTM | Average | Historical Growth | FCF Margin | Conversion | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| 3 Years | 5 Years | 3 Years | 5 Years | 10 Years | ||||||
|
Pluri Inc
NASDAQ:PLUR
|
|||||||||
|
C
|
Can Fite Biopharma Ltd
TASE:CANF
|
|||||||||
Compare company's free cash flow with its competitors.
Operating Margin
| LTM | 3Y Avg | 5Y Avg | 10Y Avg | ||
|---|---|---|---|---|---|
|
Pluri Inc | ||||
|
C
|
Can Fite Biopharma Ltd | ||||
Net Margin
| LTM | 3Y Avg | 5Y Avg | 10Y Avg | ||
|---|---|---|---|---|---|
|
Pluri Inc | ||||
|
C
|
Can Fite Biopharma Ltd | ||||
Solvency Comparison
Compare company's equity waterfall with its competitors.
Stocks Performance
Stocks Performance
PLUR, CANF
Performance By Year
PLUR, CANF
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
| FR |
|
Pharnext SCA
OTC:PNEXF
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
|
| US |
S
|
Seagen Inc
F:SGT
|